Looking for a stock that might be in a good position to beat earnings at its next report? Consider ACADIA Pharmaceuticals Inc.ACAD, a firm in the Medical - Biomedical and Genetics industry, which ...
ACADIA significantly exceeded the Q3 revenue estimates. Nuplazid’s uptake has been solid since launch and the company is improving access and giving away a lot of free samples. Which leads me to ...
ACADIA Pharmaceuticals Inc.ACAD is scheduled to report second-quarter 2017 results on Aug 8 after the closing bell. The company's track record has been dismal. Evidently, ACADIA missed estimates in ...
When you gather enough facts and figures and listen to 30-minute powerpoint presentations before even driving something, you’re left with a dialed-in expectation of what a product will deliver. Then ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results